Patent · US Active

Tear lipocalin muteins binding IL-4 r alpha

US10898545B2 · kind B2 · utility

0Cited by

15References

15Claims

0Family size

Assignees

ASTRAZENECA AB · SE
Pieris Pharmaceuticals GmbH · DE

Inventors

Andreas Hohlbaum · Paunzhausen, DE
Alexandra Baehre · Farum, DK
Gabriele Matschiner · Munich, DE
Stefan Trentmann · Freising, DE
Klaus Kirchfeld · Petershausen, DE
Hans-Juergen Christian · Moosburg an der Isar, DE

Key dates

Filing date	Jan 24, 2019
Grant date	Jan 26, 2021
Priority date	—
Expiry date	Mar 2, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha. The sequences of the muteins comprise particular combinations of amino acids. In particular a mutated amino acid residue is present at any one or more of the sequence positions 27, 28 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the linear polypeptide sequence of the mature human tear lipocalin. A mutated amino acid residue is also present at any 2 or more of the sequence positions 26, 32, 34, 55, 56, 58 and 63 of the linear polypeptide sequence of the mature human tear lipocalin. The invention also provides a corresponding nucleic acid molecule encoding such a mutein and a method for producing such a mutein and its encoding nucleic acid molecule.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.